Menu
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Forum
No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700
www.novocure.com
https://www.investing.com/news/company-news/novocure-shares-get-price-target-boost-on-positive-outlook-93CH-3372898
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune system’s ability to combat Jetzt den vollständigen Artikel lesen
No summary available.
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, Jetzt den vollständigen Artikel lesen
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.
Novocure had good news mixed with some not-so-good news.
NovoCure''s METIS trial results raise doubts about TTFields'' efficacy in NSCLC treatment, leading to a sell recommendation for NVCR stock. Read more here.
Novocure Ltd.’s stock soared 15% Wednesday after the company announced positive results from a late-stage trial of a medtech device to treat patients with lung cancer that has spread to their brains.
https://www.investing.com/news/company-news/novocure-shares-target-raised-on-metis-trial-optimism-93CH-3355430
Wednesday, Novocure Ltd (NASDAQ: NVCR ) released data from the Phase 3 METIS clinical trial of Tumor Treating Fields (TTFields) therapy . The study met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial (within skull/brain) progression for adult patients treated with TTFields therapy and supportive care compared to supportive care alone for 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery. Tumor Treating Fields is a cancer therapy that uses … Full story available on Benzinga.com